Clinical trial
A Phase I Safety and Tolerability Study of LBH589 in Combination With Sorafenib in Patients With Advanced Renal Cell Carcinoma, Soft Tissue Sarcoma, and Non-small Cell Lung Carcinoma (NSCLC) of Non-squamous Histologies.
NCT01005797 is registered in ClinicalTrials.gov with Medical University of South Carolina as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Safety and Tolerability Study of LBH589 in Combination With Sorafenib in Patients With Advanced Renal Cell Carcinoma, Soft Tissue Sarcoma, and Non-small Cell Lung Carcinoma (NSCLC) of Non-squamous Histologies.
- Lead sponsor
- Medical University of South Carolina
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2009
- Completion date
- January 31, 2017
- Enrollment
- 38 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
non small cell lung cancer (nsclc), renal cancer, soft tissue sarcoma